Start Over

Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19.

Authors :: Fragiel M
Miró Ò
Llorens P
Jiménez S
Piñera P
Burillo G
Martín A
Martín-Sánchez FJ
García-Lamberechts EJ
Jacob J
Alquézar-Arbé A
Juárez R
Jiménez B
Del Rio R
Mateo Roca M
García AH
López Laguna N
Lopez Diez MP
Pedraza García J
Fernández de Simón Almela A
Lopez Diaz JJ
Eiroa Hernández P
Ruiz de Lobera N
Porta-Etessam J
Fernández Pérez C
Calvo E
González Del Castillo J
Source :: Annals of neurology [Ann Neurol] 2021 Mar; Vol. 89 (3), pp. 598-603. Date of Electronic Publication: 2020 Dec 28.
Publication Year :: 2021
Abstract: We diagnosed 11 Guillain-Barré syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2-month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15‰) than non-COVID (0.02‰) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18-12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant-years, respectively, OR = 13.5, 95% CI = 9.87-18.4). Regarding clinical characteristics, olfactory-gustatory disorders were more frequent in COVID-GBS than non-COVID-GBS (OR = 27.59, 95% CI = 1.296-587) and COVID-non-GBS (OR = 7.875, 95% CI = 1.587-39.09) patients. Although COVID-GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS-CoV-2 could be another viral infection causing GBS. ANN NEUROL 2021;89:598-603.<br /> (© 2020 American Neurological Association.)